Search results
AI finds plethora of potential sources for new antibiotics to fight superbugs | Fox 11 Tri Cities...
FOX 11/41 Yakima· 22 hours agoHundreds of thousands of potential sources of new antibiotics to fight deadly drug-resistant...
Canadian Optimi To Export Magic Mushrooms To Australia - Lululemon Athletica (NASDAQ:LULU), Optimi...
Benzinga· 12 hours agoThe Magic Mushrooms and MDMA market is hitting new milestones. Canada has licensed Optimi Health...
Magic Mushrooms Get Canadian Export License in Psychedelic Race
Bloomberg via Yahoo Finance· 3 days ago(Bloomberg) -- Canada has licensed a startup to export psychedelics to Australia for patient use,...
Bone Medications Transform Into Fungal Fighters in Groundbreaking Study
SciTechDaily· 24 hours agoCombining azoles with bisphosphonates enhances the treatment of fungal infections, showing...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoLive from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM PR Newswire SUZHOU, China, and ROCKVILLE, Md., June 4, 2024 ...
U.S. maternal death rate far exceeds that of other wealthy nations
UPI· 2 days agoIn 2022, U.S. women had a death rate from complications of pregnancy and childbirth of 22 deaths per...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoTLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing ...
FDA Clearance For Gastrointestinal Parasite Detection Kit
StreetInsider· 2 days agoMELBOURNE, Australia, June 4, 2024 /PRNewswire/ -- Genetic Signatures Limited [ASX:GSS] ("GSS" or the "Company"), a global molecular diagnostics...
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical...
Valley City Times Record· 3 days agoSutro, a clinical-stage oncology company pioneering site...the randomized portion (Part 2) of REFRαME-O1, a global, registration-directed clinical trial of luvelta (NCT05870748) in platinum- ...
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion...
Tehachapi News· 5 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...